(Cervical Cancer) Keytruda Combined with Chemotherapy as First-Line Treatment
(Cervical Cancer) Keytruda Combined with Chemotherapy as First-Line Treatment
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Cervical Cancer) Keytruda Combined with Chemotherapy as First-Line Treatment
- July 9, 2021
- 1 min read
On June 22, 2021, Merck announced the efficacy and safety evaluation of anti-PD-1 antibody Keytruda combined with chemotherapy as first-line treatment for persistent, recurrent, and metastatic cervical cancer in the KEYNOTE-826 Phase III clinical trial, with the primary endpoints of overall survival and progression-free survival meeting the prespecified benchmarks.
The KEYNOTE-826 Phase III clinical trial was a randomized triple-blind trial that enrolled patients with persistent, recurrent, and metastatic cervical cancer (N=617), divided into a group receiving Keytruda 200 mg plus investigator-selected chemotherapy in 21-day treatment cycles, and a group receiving placebo plus investigator-selected chemotherapy. The primary endpoints were overall survival and progression-free survival, with secondary endpoints including objective response rate, duration of response, and safety.
The interim analysis results of the KEYNOTE-826 trial showed that compared to the placebo + chemotherapy group, the Keytruda + chemotherapy group demonstrated significant improvement in both overall survival and progression-free survival regardless of PD-L1 expression status. The safety profile was consistent with the known safety profile of the drugs.
-
Investigational Drugs
-
Immunotherapy
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.